Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer

被引:32
作者
Gemer, O [1 ]
Segal, S [1 ]
Kopmar, A [1 ]
机构
[1] Ben Gurion Univ Negev, Fac Hlth Sci, Barzilai Med Ctr, Dept Obstet & Gynecol, IL-78306 Ashkelon, Israel
关键词
CA; 125; cytoreduction; ovarian cancer;
D O I
10.1034/j.1600-0412.2001.080006583.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background. Suboptimal cytoreduction of advanced ovarian cancer is related to initial tumor bulk which correlates with CA125 level. Methods. Retrospective record study of 40 patients with stage III ovarian cancer. The ability of a CA125 threshold level of 500 U/mL to predict suboptimal cytoreduction was determined. Results. Twenty-four (60%) of the patients were optimally cytoreduced. At the CA125 cut off level of 500 U/mL the sensitivity for predicting suboptimal debulking was 62% and specificity was 83%. Above a CA 125 level of 1500 U/mL none of the patients were optimally cytoreduced. Conclusions. More data are needed to determine the CA125 cut off level at which the standard approach of initial laparotomy and cytoreduction may be modified.
引用
收藏
页码:583 / 585
页数:3
相关论文
共 12 条
[1]   Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125 [J].
Berek, JS .
GYNECOLOGIC ONCOLOGY, 2000, 77 (02) :225-226
[2]   The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma [J].
Chi, DS ;
Venkatraman, ES ;
Masson, V ;
Hoskins, WJ .
GYNECOLOGIC ONCOLOGY, 2000, 77 (02) :227-231
[3]  
Geisler JP, 1996, J REPROD MED, V41, P140
[4]  
Griffiths C T, 1975, Natl Cancer Inst Monogr, V42, P101
[5]   Cytoreduction for advanced ovarian cancer in perspective [J].
Hacker, NF .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 (02) :159-160
[6]  
HACKER NF, 1983, OBSTET GYNECOL, V61, P413
[7]   THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA [J].
HOSKINS, WJ ;
MCGUIRE, WP ;
BRADY, MF ;
HOMESLEY, HD ;
CREASMAN, WT ;
BERMAN, M ;
BALL, H ;
BEREK, JS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 170 (04) :974-980
[8]   THE INFLUENCE OF CYTOREDUCTIVE SURGERY ON RECURRENCE-FREE INTERVAL AND SURVIVAL IN SMALL-VOLUME STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
HOSKINS, WJ ;
BUNDY, BN ;
THIGPEN, JT ;
OMURA, GA .
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :159-166
[9]  
OZOIS RF, 1997, PRINCIPLES PRACTICE, P919
[10]   Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival [J].
Schwartz, PE ;
Rutherford, TJ ;
Chambers, JT ;
Kohorn, EI ;
Thiel, RP .
GYNECOLOGIC ONCOLOGY, 1999, 72 (01) :93-99